Bayer was not granted an injunction in preliminary proceedings because the Court found that there was a serious chance that Bayer’s patent would be held invalid.
The fact that the patent had survived opposition before the EPO was of no influence since new, closer prior art had subsequently been found.
Read the complete article by Bart van Wezenbeek on Kluwer IP Law.
